Topiroxostat is a non-purine selective xanthine oxidase inhibitor indicated for the treatment of gout and hyperuricemia.
I. Pharmaceutical Properties and Mechanism of Action
1. Active Ingredient and Dosage Form
(1) Topiroxostat is available in tablet form.
(2) Excipients include lactose hydrate, microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, and magnesium stearate.
2. Mechanism of Action
(1) Topiroxostat blocks the uric acid production pathway by competitively inhibiting xanthine oxidoreductase.
(2) This drug is highly selective for xanthine oxidase and has no significant inhibitory effect on other purine and pyrimidine metabolic enzymes, thereby reducing serum uric acid while minimizing interference with normal metabolism.
II. Drug-Drug Interactions and Medication Management
1. Absolutely Contraindicated Concomitant Medications
Mercaptopurine hydrate, Azathioprine: By inhibiting xanthine oxidase, topiroxostat may cause a marked increase in plasma concentrations of the above drugs, leading to severe myelosuppression. Concomitant use is prohibited.
2. Drugs Requiring Cautious Concomitant Use
(1) Warfarin: May enhance anticoagulant effects; coagulation function should be monitored during co-administration.
(2) Vidarabine: May potentiate neurotoxicity (e.g., hallucinations, tremors).
(3) Xanthine derivatives such as theophylline: May increase their plasma concentrations, requiring dosage adjustment.
(4) Didanosine: May increase its plasma concentration; concomitant use requires caution.
3. Effects on Hepatic Enzymes
(1) In vitro studies show that topiroxostat exerts certain inhibitory effects on CYP2C8/9, 1A1/2, 3A4, and 2C19, but has no significant impact on CYP2A6, 2B6, 2D6, and 2E1.
(2) Potential drug interactions should be noted when co-administered with drugs metabolized by the above enzymes.
4. Effects on Drug Transporters
Topiroxostat inhibits transporters including OAT3, OAT1, BCRP, and OATP1B1, which may affect renal excretion and hepatic uptake of other drugs.
III. Management of Missed Doses and Overdosage
1. Management of Missed Doses
(1) If a dose is missed, it should be taken as soon as possible; however, if it is nearly time for the next dose (e.g., less than 6 hours until the next scheduled dose), the missed dose should be skipped and the next dose taken as planned.
(2) A double dose should never be taken at one time, as a sudden rise in plasma concentration may increase the risk of adverse reactions.
2. Management of Overdosage or Accidental Intake
In case of accidental overdosage, close monitoring is required for symptoms such as nausea, abdominal pain, abnormal liver function, and elevated indicators of renal tubular injury. No specific antidote is currently available, and treatment is mainly symptomatic and supportive:
(1) Emesis or gastric lavage may be considered in early-stage overdosage.
(2) Monitor liver function, renal function, and blood routine.
(3) In the event of severe liver or renal injury, discontinue the drug and administer appropriate treatment.
3. Recommendations for Medication Adherence
(1) It is recommended to take the medication at fixed times every morning and evening to form a habit.
(2) Pill boxes or mobile phone reminders may be used to reduce missed doses.
(3) Do not increase the dosage on your own after a missed dose, nor discontinue treatment arbitrarily.
(4) If a gout flare occurs during the initial treatment period, the drug should not be stopped; continue the original dosage and use anti-inflammatory drugs concomitantly to control symptoms.
4. Special Precautions
(1) The tablets must be removed from the PTP blister pack before administration; do not swallow the entire blister pack to avoid esophageal injury caused by sharp edges.
(2) Seek medical attention promptly if symptoms such as rash, jaundice, abnormal urine output, or marked fatigue occur.
